Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$119.33 USD

119.33
1,442,135

-1.97 (-1.62%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $119.42 +0.09 (0.08%) 4:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy Amid Recovering Prospects

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.

CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?

We expect brand price inflation, new product launch, higher utilization and new PBM clients to have contributed to second-quarter growth for CVS Health (CVS).

Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?

Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.

Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will US Business Strength Aid Acadia's (ACHC) Q2 Earnings?

Strength in US operations, stemming from higher patient days and revenue per patient day, is expected to have aided Acadia Healthcare's (ACHC) Q2 performance. Rising expenses are likely to have partially offset the same.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?

Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.

Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?

Zimmer Biomet (ZBH) is expected to have witnessed procedure recovery in its legacy business in the second quarter.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

STERIS (STE) Set to Post Q1 Earnings: What's in the Cards?

STERIS' (STE) first-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.

ZBH or PODD: Which Is the Better Value Stock Right Now?

ZBH vs. PODD: Which Stock Is the Better Value Option?

GE HealthCare (GEHC) to Report Q2 Earnings: What's in Store?

GE HealthCare's (GEHC) Imaging revenue growth in Q2 is expected to have been led by Magnetic Resonance as well as its molecular imaging entity.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?

IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.

Why Zimmer (ZBH) Could Beat Earnings Estimates Again

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023

Here's Why You Should Invest in Edward Lifesciences (EW) Now

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.

Alcon (ALC) Gains From Robust Contact Lense Sales, Launches

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.

Align Technology's (ALGN) New Pacts, Innovation Aid Growth

Align Technology's (ALGN) Invisalign comprehensive witnesses strong initial adoption in the market.

Labcorp (LH) Completes Strategic Deal With Jefferson Health

Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.

Quest Diagnostics (DGX) Brings New Test for Prostate Cancer

Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.

Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health

Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors remain optimistic about QIAGEN (QGEN) backed by the performance of the NGS portfolio and diagnostic solutions.

Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System

Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.